In a report released today, Nicole Germino from Truist Financial maintained a Buy rating on Perspective Therapeutics (CATX – Research Report).

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Perspective Therapeutics (CATX – Research ...

Perspective Therapeutics shares interim results for [212Pb]VMT-α-NET trial, showing promising safety, stable disease cases, ...

Large pill size, high pill burden and palatability were identified as key barriers for phosphate binder adherenceLOS ALTOS, ...

Wedbush reissued their outperform rating on shares of Perspective Therapeutics (NYSE:CATX – Free Report) in a report released ...

Perspective Therapeutics Inc (CATX) stock saw a modest uptick, ending the day at $4.01 which represents a slight increase of $0.38 or 10.47% from the prior close of $3.63. The stock opened at $3.64 ...

On Friday, Perspective Therapeutics, Inc. (NYSE:CATX) revealed updated interim results from its ongoing Phase 1/2a trial of [212Pb]VMT-α-NET. The data will be presented at the 2025 American ...

Capital Markets increased its price target on Perspective Therapeutics Inc (NYSE:CATX) shares to $20.00, up from the previous $15.00, while maintaining a Buy rating on the stock. The $259.2 million ...

Unicycive Therapeutics, Inc. has announced the publication of a review in the Journal of Nephrological Science that explores patient perspectives on phosphate management in chronic kidney disease ...

On Friday, Perspective Therapeutics, Inc. (NYSE:CATX) revealed updated interim results from its ongoing Phase 1/2a trial of [212Pb]VMT-α-NET. The data will be presented at the 2025 American Society of ...